2,589
Views
1
CrossRef citations to date
0
Altmetric
Allergy

The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients

, ORCID Icon, , , ORCID Icon, , , & show all
Pages 220-229 | Received 13 Dec 2021, Accepted 20 Jan 2022, Published online: 09 Feb 2022

References

  • Titulaer J, Arefian H, Hartmann M, et al. Cost-effectiveness of allergic rhinitis treatment: an exploratory study. SAGE Open Med. 2018;6:205031211879458.
  • Baena-Cagnani CE. The global burden of asthma and allergic diseases: the challenge for the new century. Curr Allergy Asthma Rep. 2001;1(4):297–298.
  • Okubo K, Kurono Y, Ichimura K, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69(3):331–345.
  • Matsubara A, Sakashita M, Gotoh M, et al. Survey of allergic rhinitis in Japan 2019. Nippon Jibiinkoka Gakkai Kaiho Tokyo. 2020;123(6):485–490.
  • Sasaki K, Okamoto Y, Yonekura S, et al. Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists. Int Arch Allergy Immunol. 2009;149(4):350–358.
  • Yamada T, Saito H, Fujieda S. Present state of japanese cedar pollinosis: the national affliction. J Allergy Clin Immunol. 2014;133(3):632–639.e5.
  • Okubo K, Okuda M. An internet survey of allergic rhinitis patients (written in Japanese). 2012;19(1):113–124.
  • Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286.e9.
  • Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5(1):8191.
  • Nishima S, Kozawa M, Milligan KL, et al. Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children. Asia Pac Allergy. 2019;9(1):e7.
  • Okubo K, Ogino S, Nagakura T, et al. Omalizumab is effective and safe in the treatment of japanese cedar pollen-induced seasonal allergic rhinitis. Allergol. Int. 2006;55(4):379–386.
  • Okubo K, Okano M, Sato N, et al. Add-On omalizumab for inadequately controlled severe pollinosis despite standard-of-Care: a randomized study. J Allergy Clin Immunol Pract. 2020;8(9):3130–3140.e2.
  • Cardell L-O, Olsson P, Andersson M, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26(1):15082.
  • Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(5):113–141.
  • Nishiike S, Ogino S, Irifune M, et al. Measurement of quality of life during different clinical phases of japanese cedar pollinosis. Auris Nasus Larynx. 2004;31(2):135–139.
  • Kulthanan K, Chusakul S, Recto MT, et al. Economic burden of the inadequate management of allergic rhinitis and urticaria in asian countries based on the GA²LEN Model. Allergy Asthma Immunol Res. 2018;10(4):370–378.
  • Zuberbier T, Lötvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–1279.
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353–365.
  • Gotoh M, Yuta A, Okano M, et al. Severity assessment of Japanese cedar pollinosis using the practical guideline for the management of allergic rhinitis in Japan and the allergic rhinitis and its impact on asthma guideline. Allergol Int. 2013;62(2):181–189.,
  • Nakamura S, Tsunoda S, Sakaida H, et al. Analysis of factors associated with cedar pollen sensitization and development of pollinosis in a young Japanese adult population. Allergol Int. 2019;68(1):39–45.
  • E-Stat. Population Estimates by Age: February 1, 2020 (Final estimates). 2020; [cited 2020 Sep 29]. http://www.stat.go.jp/data/jinsui/pdf/202007.pdf.
  • E-Stat. Basic Survey on Wage Structure in 2019 – Table 1 by job category-Amount of cash earnings, predetermined amount of earnings, annual bonuses, and other special earnings to be regularly paid by job category (industrial total). 2020; [cited 2020 Sep 29]. https://www.e-stat.go.jp/dbview?sid=0003084610.
  • E-Stat. Summary tables, Time Series, Table 15 Labour force participation rate by age group for 2019. 2020; [cited 2020 Aug 29]. Available from: https://www.stat.go.jp/english/data/roudou/results/month/index.html.
  • E-stat. Labour Force Survey Basic Aggregation All Prefectures Nationwide Monthly -Average monthly working days of employees by industry and occupation (January 2013-)-12th and 13th revised industry classification and December 2009 revised occupation classification, Table 2-11-2. 2020; [cited 2020 Sep 29]. Available from: https://www.e-stat.go.jp/dbview?sid=0003074700.
  • Statistic Bureau of Japan. Survey on Time Use and Leisure Activities. 2016; [cited 2020 Sep 29]. Available from: https://www.stat.go.jp/english/data/shakai/index.html.
  • Pharmaceuticals and Medical Devices Agency. Omalizumab Optimal Use Guideline (written in Japanese). 2019; [cited 2019 Nov]. Available from:https://www.pmda.go.jp/files/000232879.pdf.
  • Pharmaceuticals and Medical Devices Agency. Omalizumab Summary of Application; [cited 2019 Nov 12]. Available from: https://www.pmda.go.jp/drugs/2019/P20191119001/index.html.
  • Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011;72(2):185–192.
  • Reid MG. Economics of household production. New York: J. Wiley & Sons; 1934.
  • Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–477.
  • Brouwer WBF, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6(5):511–514.
  • Miranda V. Cooking, caring and volunteering: unpaid work around the world. OECD, OECD Social, Employment and Migration Working Papers 116, Sep 2011.
  • Gelhorn HL, Balantac Z, Ambrose CS, et al. Patient and physician preferences for attributes of biologic medications for severe asthma. Patient Prefer. Adherence. 2019;13:1253–1268.
  • Cox LS, Murphey A, Hankin C. The cost-effectiveness of allergen immunotherapy compared with pharmacotherapy for treatment of allergic rhinitis and asthma. Immunol Allergy Clin North Am. 2020;40(1):69–85. Feb.
  • Okamoto Y. Review: prospects for sublingual immunotherapy for allergic rhinitis. Nippon Jibiinkoka Gakkai Kaiho. 2019;122(11):1381–1385.
  • Yonekura S, Okamoto Y, Horiguchi S, et al. Effects of aging on the natural history of seasonal allergic rhinitis in middle-aged subjects in South chiba, Japan. Int Arch Allergy Immunol. 2012;157(1):73–80.
  • Bousquet J, Schünemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–1062.
  • Bousquet P, van Cauwenberge N. Khaltaev J. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–S334.
  • Sakashita M, Hirota T, Harada M, et al. Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population. Int Arch Allergy Immunol. 2010;151(3):255–261.
  • Spickett G. Oxford handbook of clinical immunology and allergy, Fourth edition. Oxford (UK); New York (NY): Oxford University Press, 2020.
  • Sasaki K, Ohshiro T, Sakio R, et al. Efficacy of seasonal allergic rhinitis using an 810 nm diode laser system: 810 nm diode laser for allergic rhinitis. Laser Ther. 2019;28(1):11–18.,
  • Minami Y, et al. Comparison of quality of life between patients with Japanese sedar pollinosis ans atopic patients with the SF-8 health status questionnaire. Allergy. 2010;(64):451.
  • Tokyo Metropolitan Institute of Public Health. Pollen Disperse Status 2019. 2020; [cited 2020 Sep 29]. Available from: http://www.tokyo-eiken.go.jp/.
  • Böckerman P, Ilmakunnas P. The job satisfaction-productivity nexus: a study using matched survey and register data. ILR Rev. 2012;65(2):244–262.
  • Colás C, Brosa M, Antón E, et al. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN study. Allergy. 2017;72(6):959–966.
  • Himmler S, Mueller M, Sherif B, et al. A case study applying a novel approach to estimate the social impact of a medical innovation – the use of secukinumab for psoriatic arthritis in Germany. Expert Rev. Pharmacoecon. Outcomes Res. 2019;2019:1–9.
  • Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22(6):1203–1210.
  • Nakae K, Baba K. Update on epidemiology of pollinosis in Japan: changes over the last 10 years: update on epidemiology of pollinosis in Japan. Clin. Exp. Allergy Rev. 2010;10(1):2–7.
  • Lieberman P. and Anderson J. A., Eds., Allergic diseases: diagnosis and treatment, 3rd ed. Totowa (NJ): Humana; 2007.